E-viri
Recenzirano
Odprti dostop
-
Sempere, Abiu; Viñado, Belén; Los-Arcos, Ibai; Campany, David; Larrosa, Nieves; Fernández-Hidalgo, Nuria; Rodríguez-Pardo, Dolors; González-López, Juan José; Nuvials, Xavier; Almirante, Benito; Escolà-Vergé, Laura
Antimicrobial agents and chemotherapy, 10/2022, Letnik: 66, Številka: 10Journal Article
This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.
